Skip to main content

. 1982 Sep;48(3):304–305. doi: 10.1136/hrt.48.3.304

Effects of prostaglandin E1 and other vasodilator agents in pulmonary hypertension of scleroderma.

M Baron, G Skrinskas, R Hyland, M B Urowitz

PMCID: PMC481250 PMID: 7201844

304

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

BERGSTROM S., DUNER H., von EULER U., PERNOW B., SJOVALL J. Observations on the effects of infusion of prostaglandin E in man. Acta Physiol Scand. 1959 Mar 31;45:145–151. doi: 10.1111/j.1748-1716.1959.tb01686.x. [DOI] [PubMed] [Google Scholar]
Carlson L. A., Olsson A. G. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet. 1976 Oct 9;2(7989):810–810. doi: 10.1016/s0140-6736(76)90653-x. [DOI] [PubMed] [Google Scholar]
Guadagni D. N., Ikram H., Maslowski A. H. Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension. Br Heart J. 1981 Apr;45(4):385–388. doi: 10.1136/hrt.45.4.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
Szczeklik J., Dubiel J. S., Mysik M., Pyzik Z., Krol R., Horzela T. Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension. Br Heart J. 1978 Dec;40(12):1397–1401. doi: 10.1136/hrt.40.12.1397. [DOI] [PMC free article] [PubMed] [Google Scholar]
Szczeklik J., Szczeklik A., Nizankowski R. Prostacyclin for pulmonary hypertension. Lancet. 1980 Nov 15;2(8203):1076–1076. doi: 10.1016/s0140-6736(80)92291-6. [DOI] [PubMed] [Google Scholar]
Watkins W. D., Peterson M. B., Crone R. K., Shannon D. C., Levine L. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet. 1980 May 17;1(8177):1083–1083. doi: 10.1016/s0140-6736(80)91522-6. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES